Stage 3 Melanoma Treatment: What Is Adjuvant Therapy?

Quick note (because your health deserves the fine print): This article is for education, not a replacement for medical advice. Stage 3 melanoma treatment is highly personalizedyour oncology team will tailor decisions to your exact stage, pathology, and overall health.

Stage 3 Melanoma in Plain English

Stage 3 melanoma generally means the melanoma has moved beyond the original skin spot and involved nearby lymph nodes or nearby skin/lymph channels (often called “satellite” or “in-transit” disease). The key idea: it’s regional spread, not distant spread to organs like the lungs or liver.

Because stage 3 includes a rangefrom tiny microscopic cells found in a sentinel lymph node to larger, clinically obvious lymph node diseaseyour recurrence risk can vary a lot. That’s why you’ll hear doctors talk about stage 3 subgroups (IIIA, IIIB, IIIC, IIID) and “tumor burden.” Translation: stage 3 is not one-size-fits-all, and neither is the treatment plan.

The Big Goal: Remove What’s Visible, Treat What Might Be Invisible

Most stage 3 melanoma plans start with surgery, typically:

• Wide local excision (removing the melanoma with a margin of normal-looking skin).
• Lymph node evaluation (often sentinel lymph node biopsy, and sometimes additional lymph node surgery depending on findings and symptoms).

After surgery, scans and exams may show “no evidence of disease.” That’s great newsbut melanoma can be sneaky. Microscopic cells can sometimes remain, too small to show up on imaging. This is where adjuvant therapy steps in.

So… What Is Adjuvant Therapy?

Adjuvant therapy is treatment given after the main treatment (usually surgery) to reduce the chance the cancer comes back. Think of surgery as taking out the big weeds you can see, and adjuvant therapy as treating the soil so any tiny leftover seeds don’t throw a sequel.

Why adjuvant therapy matters in stage 3

Stage 3 melanoma has a meaningful risk of recurrence compared with earlier stages. Adjuvant therapy aims to:

• Lower the risk of the melanoma returning in nearby lymph nodes or skin
• Lower the risk of melanoma spreading elsewhere later
• Improve “recurrence-free survival” (how long you stay cancer-free after treatment)

Who Should Consider Adjuvant Therapy?

After a complete resection, adjuvant therapy is often discussed for many people with stage 3 melanomabut not always automatically. The decision usually depends on:

• Exact stage (IIIA vs IIID) and key pathology details (like how much cancer was in the lymph node)
• Mutation status (especially BRAF V600, which can open targeted therapy options)
• Your medical history (autoimmune disease, transplant history, chronic conditions)
• Preferences and lifestyle (infusions vs pills, travel distance, work schedule)
• Risk tolerance (some people want to be aggressive; others prioritize avoiding side effects)

A real-life decision fork

Example A: Someone with stage IIIA melanoma and a very small amount of cancer found only in a sentinel node may consider active surveillance if the expected benefit is small.

Example B: Someone with stage IIIC melanoma and multiple involved nodes may lean strongly toward adjuvant systemic therapy because recurrence risk is higher.

Adjuvant Therapy Options for Stage 3 Melanoma

For stage 3 melanoma, adjuvant therapy usually means systemic therapytreatment that travels through the bloodstream to reach cells anywhere in the body. The two main categories are:

1. Immunotherapy (most commonly PD-1 inhibitors)
2. Targeted therapy (for BRAF V600–mutated melanoma)

Option 1: Immunotherapy (PD-1 inhibitors)

PD-1 inhibitors are medicines that help your immune system recognize and attack melanoma cells. In a simplified metaphor: the immune system has “brakes,” and PD-1 is one of them. These drugs help release that brake so immune cells can do their job more effectively.

The most common adjuvant immunotherapies in stage 3 melanoma include:

• Pembrolizumab (Keytruda)
• Nivolumab (Opdivo)

They’re typically given as an IV infusion on a regular schedule for up to about a year (exact schedules vary).

Pros of adjuvant immunotherapy

• Can be used regardless of BRAF mutation status
• Often well-tolerated, with many people able to continue school/work with adjustments
• Has strong evidence for lowering recurrence risk in resected high-risk melanoma

Trade-offs and side effects

Immunotherapy side effects happen because revving up the immune system can sometimes lead it to irritate normal tissues. Many side effects are manageable, but some can be serious. Common categories include:

• Skin: rash, itching
• GI: diarrhea, colitis-like inflammation
• Hormones: thyroid changes, adrenal or pituitary inflammation (can cause fatigue, headaches, mood changes)
• Liver/lungs: inflammation that may show up on labs or as cough/shortness of breath

Important practical tip: your team will usually tell you to report new symptoms early rather than “tough it out.” With immunotherapy, timing matters.

Option 2: Targeted therapy (for BRAF V600–mutated melanoma)

If your melanoma has a BRAF V600 mutation, targeted therapy may be an option after surgery. The most established adjuvant targeted combination is:

• Dabrafenib (Tafinlar) + Trametinib (Mekinist)

These are oral medications taken on a schedule for about a year in many adjuvant protocols.

Pros of targeted therapy

• Often works quickly (mechanism is direct blocking of growth pathways)
• Oral meds can be more convenient than infusion visits for some people
• Strong evidence for reducing recurrence risk in BRAF-mutant stage 3 melanoma

Trade-offs and side effects

Targeted therapy side effects are different from immunotherapy and may include:

• Fever/chills (a signature issue for dabrafenib + trametinib)
• Fatigue
• Skin issues: rash, sensitivity
• GI symptoms: nausea, diarrhea
• Blood pressure/heart function and eye checks (your team may monitor these)

Some people do great on targeted therapy; others need dose adjustments or breaks. The plan is often flexible.

Immunotherapy vs Targeted Therapy: How Doctors Help You Choose

If you have BRAF V600–mutant melanoma, you may be choosing between two strong options. The “best” choice often depends on your context, not just the drug list.

Questions that shape the decision

• How high is my recurrence risk? (Ask for your stage and pathology details in writing.)
• What’s my BRAF status? (If you don’t know, askthis matters.)
• Which side effects worry me most? (Autoimmune risk vs fever risk, for example.)
• What fits my life right now? (Frequent infusion visits vs daily pills.)
• If the melanoma comes back, what options would we use next?

A “day-in-the-life” comparison

Immunotherapy: You show up for infusion appointments, do periodic labs, and stay alert for immune-related symptoms.

Targeted therapy: You take pills on schedule, manage potential fevers or fatigue, and do monitoring visits/labs to ensure safety.

Both require teamwork. Neither is “set it and forget it.” (Cancer treatments rarely are.)

Where Does Radiation Fit In?

Radiation is not the star of the stage 3 melanoma show, but it can play a supporting role in specific situationsespecially when there is a high risk of recurrence in a lymph node basin after surgery (for example, bulky nodal disease or certain high-risk pathology features). Your team may discuss radiation as:

• Adjuvant radiation to a lymph node area to improve local control
• Palliative radiation (if needed later for symptom relief)

Whether radiation is recommended depends heavily on your pathology and imaging.

Adjuvant Therapy vs Neoadjuvant Therapy: Don’t Mix Them Up

Adjuvant = after surgery. Neoadjuvant = before surgery.

Neoadjuvant approaches (like giving immunotherapy before surgery in certain resectable stage 3 cases) have gained attention in recent years. Not everyone is a candidate, and many people still follow the classic surgery-then-adjuvant path. If your doctor brings up neoadjuvant therapy, it’s usually because your particular stage 3 scenario fits emerging evidence or clinical trial approaches.

What to Expect During Adjuvant Therapy

Before treatment starts

• Pathology review (confirm stage and margin status)
• Molecular testing (BRAF V600 and sometimes other markers)
• Baseline labs (to compare later if side effects occur)
• Sometimes baseline imaging (varies by risk level and clinic practice)

During treatment

• Regular check-ins for symptoms and side effects
• Periodic labs (especially important for immunotherapy)
• Skin exams and follow-up visits (melanoma is a “follow-up sport,” not a one-time event)

After treatment ends

Follow-up typically continues for years and may include skin checks, lymph node exams, and imaging based on risk and symptoms. This phase can feel weirdly anticlimacticlike training for a marathon and then being told your next workout is “show up occasionally and try not to Google at 2 a.m.” (Easier said than done.)

Living With the “What If”: The Emotional Side of Adjuvant Therapy

Let’s name it: adjuvant therapy isn’t just a medical decision; it’s a psychological one. Some people choose treatment because they want to feel they’ve done everything possible. Others choose surveillance because they’d rather avoid side effects unless there’s proven disease to treat.

Neither approach is “brave” and the other “giving up.” They’re different ways of managing risk. The best plan is the one you can realistically followphysically, emotionally, and financiallywhile staying aligned with your medical situation.

FAQ: Quick Answers People Actually Want

Does adjuvant therapy guarantee melanoma won’t come back?

No. It reduces risk, but it’s not a force field. That said, reducing recurrence risk can still be a very meaningful benefitespecially in higher-risk stage 3 disease.

If I have side effects, does that mean it’s working?

Not necessarily. Some people have minimal side effects and still benefit. Some have side effects that require treatment breaks or medication changes. Your team tracks safety and benefit separately.

What if I’m offered a clinical trial?

Clinical trials can provide access to promising options and extra monitoring. If a trial is offered, it’s worth asking: “What’s the standard option outside the trial, and what is the trial testing that’s different?”

What should I bring to my oncology visit?

• A list of symptoms and questions (yes, even the “small” ones)
• Your current medications and supplements
• Someone you trust to take notes (your future self will thank you)
• A willingness to ask for a recap in plain language

Conclusion: Adjuvant Therapy Is a Strategy, Not a Punishment

Stage 3 melanoma can feel like your life got rerouted without asking permission. Adjuvant therapy is one of the main tools doctors use to lower the chance of melanoma returning after surgeryespecially for higher-risk stage 3 disease.

The headline: PD-1 immunotherapy (like pembrolizumab or nivolumab) is a major adjuvant option for many people, and BRAF-targeted therapy (dabrafenib + trametinib) is a key option when the melanoma has a BRAF V600 mutation. The best choice depends on your exact stage, your tumor biology, your health history, and what you value most in day-to-day life.

If there’s one “power move” here, it’s this: ask your team to explain your stage and recurrence risk, then discuss the benefit and trade-offs of each approach in your specific case. That’s not being difficultthat’s being appropriately in charge of your own body.

Experiences With Stage 3 Melanoma Adjuvant Therapy (What People Often Report)

These are composite, real-world-style experiences (not medical advice and not one person’s story). People’s journeys vary widely, but these themes come up again and again in clinics, support communities, and survivorship conversations.

1) “I expected one decision. I got five.”

A lot of people walk into the first post-surgery oncology visit thinking it will be a simple yes/no: “Do I need more treatment?” Instead, they get a menu: immunotherapy, targeted therapy (if BRAF-positive), surveillance, and sometimes a discussion about clinical trials. Add in staging details (IIIA vs IIIC), pathology terms, and lab testingand it can feel like you need a translator and a snack. Many patients say the turning point is asking the doctor to slow down and summarize: “What are the two most reasonable options for me, and why?” That question often turns overwhelm into a plan.

2) The infusion chair becomes “oddly normal”

People on PD-1 immunotherapy often describe the first infusion as intimidatingnew place, new routine, new everything. Then, surprisingly, it becomes a rhythm: check-in, labs, quick symptom review, infusion, and done. Some bring headphones and a comfort playlist. Others bring a friend and call it “errands, but make it oncology.” The practical challenge is less the infusion itself and more the mental load of monitoring symptoms between visits. Many patients find it helpful to keep a simple notes app: date, symptom, severity, and whether it’s improvingso they can report clearly without trying to remember everything weeks later.

3) Targeted therapy can feel like a “daily negotiation”

For people taking dabrafenib + trametinib, the experience is often described as convenient (no infusion center) but sometimes more hands-on day-to-day. Fevers can pop up, fatigue can be real, and routines matterhydration, rest, and following the care team’s instructions for what to do if a fever hits. Some people do a full year with manageable bumps; others need pauses or adjustments. A common emotional theme is frustration: “I beat surgery, why do I feel like I’m sick again?” Over time, many people develop a personalized routine that makes the treatment feel less like an intruder and more like a temporary (annoying) roommate.

4) “I didn’t realize survivorship had its own stress”

Even when treatment is going smoothly, scan anxiety is real. People describe the days before follow-up imaging or exams as emotionally loud: extra worry, trouble sleeping, a sudden urge to reorganize the entire house at midnight. Many find it helps to plan something grounding on scan daylike a favorite breakfast, a walk, or a low-stakes treat after the appointment. Some centers offer survivorship programs, counseling, or support groups, and patients often say they wish they’d used those resources earlier instead of trying to white-knuckle their way through the uncertainty.

5) Caregivers experience their own kind of burnout

Partners, parents, and close friends often become the logistics teamrides, calendars, medication reminders, symptom tracking. Caregivers frequently report feeling pressured to be “the strong one,” even while they’re scared too. One of the best shifts is making the job explicit: “Can you handle appointments and notes, and I’ll handle meds and questions?” Splitting responsibilities can reduce resentment and help everyone feel less alone. Many caregivers also benefit from hearing directly from the medical team what warning signs matter most, so they’re not living on high alert 24/7.

6) Small wins count more than people expect

People often measure success as “no recurrence,” which is understandable. But during adjuvant therapy, small wins matter: finishing a month of treatment, getting labs back stable, managing a side effect early, taking a walk on a low-energy day, or simply showing up to the appointment when you’d rather hide under a blanket. A lot of patients say the experience reshaped their definition of strengthit became less about powering through and more about communicating clearly, accepting help, and making decisions that fit their real life.

If you’re in this right now: You deserve a plan that makes medical sense and human sense. Ask questions, bring support, and remember that “I need that explained again” is a perfectly valid sentence.